Last reviewed · How we verify
NCT03308214
The Analysis of Factors Influencing the Vd of Imipenem in Septic Shock Patients
trial testing Imipenem in Septic Shock in 25 participants. Completed in 28 December 2018.
28 December 2018
Quick facts
| Lead sponsor | Southeast University, China |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 25 |
| Start date | 18 March 2018 |
| Primary completion | 28 December 2018 |
| Estimated completion | 28 December 2018 |
| Sites | 1 location across China |
Drugs / interventions tested
- Imipenem (IMIPENEM) — full drug profile →
Conditions studied
- Septic Shock — all drugs for Septic Shock →
Sponsor
Southeast University, China
Who can join
Adults 18 to 80, any sex, with Septic Shock. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study measures the plasma concentrations of imipenem in septic shock patients and non-septic shock patients and observes hypoalbuminemia and the impact of the severity of critical illness on Vd
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Association Between Pathophysiology and Volume of Distribution Among Patients With Sepsis or Septic Shock Treated With Imipenem: A Prospective Cohort Study.
Huang Y, Yang J, Xie J, Liu L, et al · · 2020 · cited 12× · PMID 32176787 · DOI 10.1093/infdis/jiz651
Verify or expand the search:
- PubMed search for NCT03308214
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Imipenem
Trials testing the same drug.
- NCT04310930 — Finding the Optimal Regimen for Mycobacterium Abscessus Treatment · Phase 2, PHASE3 · recruiting
- NCT04208763 — A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Man · NA · unknown
- NCT03733340 — Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT · Phase 2, PHASE3 · unknown
- NCT03858387 — PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients · unknown
- NCT03177720 — Evaluation of Innovative Tools in Development of Antibiotics · Phase 1 · completed
Other recruiting trials for Septic Shock
Currently open trials in the same condition.
- NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
- NCT07383103 — Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock · Phase 4 · recruiting
- NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
- NCT07264543 — Early Methylene Blue in the Microhemodynamics of Septic Patients · Phase 2, PHASE3 · recruiting
- NCT04855786 — External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients · NA · recruiting
Other Southeast University, China trials
Trials by the same sponsor.
- NCT07519512 — Effect of Early Transition to Assisted Ventilation on 28-day Successful Extubation in Critically Ill Patients · NA · recruiting
- NCT06990477 — Effect of EIT-guided PEEP in ARDS Patients With Higher Recruitability · NA · recruiting
- NCT07362537 — Enteral Nutrition Delivery in Prone Position Ventilated Patients With Moderate to Severe ARDS · NA · recruiting
- NCT07327268 — Cyclic On-off Switching of Pulmonary Blood Flow in Moderate to Severe ARDS · not yet recruiting
- NCT07284888 — Practices of Prone Positioning Ventilation in Patients With Moderate-to-Severe ARDS in Intensive Care Units: A Registry- · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03308214 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Southeast University, China
- Last refreshed: 5 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03308214.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing